Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, specializing in the development of novel therapies for metabolic and endocrine disorders. Focused on creating first-in-class or best-in-class treatments, Viking's research leverages its deep expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
Viking's pipeline includes three main compounds currently in clinical trials. VK2809, a selective thyroid hormone receptor beta agonist, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Recent data from a Phase 2b VOYAGE study showed that VK2809 achieved both its primary and secondary endpoints, demonstrating significant reductions in liver fat content and improvements in fibrosis and NASH resolution over a 52-week treatment period.
The company is also advancing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being developed for the treatment of metabolic disorders such as obesity. Phase 1 and 2 trials have indicated promising efficacy and safety profiles, with significant reductions in body weight observed in treated patients. Viking is evaluating both subcutaneous and oral formulations of VK2735, aiming to enhance patient convenience and expand market opportunities.
In the realm of rare diseases, Viking is developing VK0214, a selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). Currently in a Phase 1b clinical trial, VK0214 has shown potential benefits in treating the adrenomyeloneuropathy (AMN) form of X-ALD.
Financially, Viking reported a strong cash position of $963 million as of March 31, 2024, following a public offering of common stock. The company's strategic focus on advancing its clinical programs, coupled with its robust financial health, positions it well for future growth and development.
For more information, please visit Viking Therapeutics' website.
Viking Therapeutics (VKTX) announced its Q3 2022 financial results, reporting a net loss of $15.8 million, or $0.21 per share, compared to $13.2 million, or $0.17 per share, in Q3 2021. The company ended the quarter with $155 million in cash, supporting ongoing clinical trials for VK2809, VK2735, and VK0214, with data expected in 2023. The Phase 2b VOYAGE study for VK2809 is on track for Q4 2022 enrollment completion. Increased R&D and G&A expenses were noted, affecting the overall financial performance.
Viking Therapeutics (NASDAQ: VKTX) announced the release of its third-quarter 2022 financial results on October 26, 2022, after market close. A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates. The company's pipeline includes VK2809, in Phase 2b for NASH, and VK2735, in Phase 1 for metabolic disorders, showcasing ongoing innovation in therapies targeting metabolic and endocrine conditions.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in two investor conferences from September 12-14, 2022. At the H.C. Wainwright 24th Annual Global Investment Conference, Dr. Lian will deliver a presentation on September 14 at 12:30 PM Eastern, with a hybrid format available. Additionally, Viking management will engage in 1-on-1 meetings at the Morgan Stanley 20th Annual Global Healthcare Conference during the same dates, held at the Sheraton New York Hotel. Webcasts of the presentations will be accessible via the Viking Therapeutics website.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will participate in a fireside chat at the BTIG Biotechnology Conference 2022 on August 8-9, 2022. The event will be a hybrid format, facilitating both in-person and virtual attendance. Viking focuses on developing innovative therapies for metabolic and endocrine disorders, including its clinical programs VK2809, VK2735, and VK0214. VK2809 is currently in a Phase 2b study for non-alcoholic steatohepatitis, showing promising results for lipid and metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) reported Q2 2022 financial results, showing a net loss of $17.4 million, or $0.23 per share, compared to a loss of $15.4 million in Q2 2021. With $169 million in cash, the company is positioned to advance its clinical programs. Key updates include the VOYAGE Phase 2b study for VK2809, expected to complete enrollment in Q4 2022, and initial results from the Phase 1 study of VK2735 anticipated by year-end. Following FDA clearance, dosing for VK0214 in X-ALD patients is set to resume, with enrollment completion expected in H1 2023.
Viking Therapeutics (NASDAQ: VKTX) announced it will release its second quarter 2022 financial results on July 27, 2022, after market close. A conference call discussing these results and corporate updates is scheduled for 4:30 p.m. Eastern Time on the same day. Interested parties can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 internationally. For more details on the company's clinical programs, including VK2809 and VK2735, which target metabolic and endocrine disorders, visit www.vikingtherapeutics.com.
Viking Therapeutics (VKTX) announced the FDA has lifted the clinical hold on its Phase 1b trial for VK0214, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The hold was lifted after an in vivo genotoxicity study showed no adverse effects. Enrollment for the trial will resume shortly. VK0214, a thyroid hormone beta receptor agonist, has achieved orphan drug designation and previously demonstrated encouraging safety and efficacy in earlier trials. The Phase 1b study targets patients with the AMN form of X-ALD, with primary objectives focused on safety and tolerability.
Viking Therapeutics, Inc. (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., participate in a fireside chat at the William Blair Biotech Focus Conference 2022 on July 12-13, 2022. The event will be held at The St. Regis, New York, with a webcast available starting July 11, 2022. Viking is focused on developing novel therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for NASH and VK0214 for X-ALD. For more details, visit www.vikingtherapeutics.com.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The presentation will be available online on May 24 at 7:00 a.m. Eastern. This hybrid conference includes both in-person and virtual participation. Viking's clinical programs focus on metabolic and endocrine disorders, with ongoing studies for VK2809, VK0214, and VK2735. VK2809 is currently in a Phase 2b trial for NASH and fibrosis, following successful Phase 2a results for NAFLD.
Viking Therapeutics (VKTX) reported its Q1 2022 financial results, showing a net loss of $16.1 million ($0.21 per share), up from $14 million ($0.19 per share) year-over-year. The company highlighted the ongoing Phase 2b VOYAGE study for VK2809 in NASH, with enrollment completion expected in 2H22. Additionally, the Phase 1 trial of VK2735 is ongoing, with results anticipated by year-end. With a cash balance of $185 million, Viking maintains a strong financial position to support its clinical programs through key upcoming data readouts.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
What is the focus of Viking Therapeutics, Inc.?
What are the main compounds in Viking's clinical pipeline?
What recent achievements has Viking Therapeutics reported?
What financial condition is Viking Therapeutics currently in?
What are the potential treatments being developed by Viking for metabolic disorders?
How does VK2735 work?
What is VK0214 targeting?
What significant clinical milestones has VK2809 achieved?
How is Viking Therapeutics funded for its operations?
Where can I get more information about Viking Therapeutics?
